Known Medicine

Executive Summary

Known Medicine is pioneering a predictive platform that determines the optimal treatment for individual cancer patients by observing drug responses in living cells. Unlike traditional genetic profiling or static biomarker tests, the company’s technology cultures patient-derived tumor cells and exposes them to various therapies, directly measuring efficacy in a functional assay. This approach addresses the critical challenge of cancer heterogeneity, where each patient’s disease behaves uniquely. By providing real-time, actionable data on drug sensitivity, Known Medicine aims to reduce trial-and-error prescribing and improve outcomes. Founded in 2020 and based in San Francisco, the company is part of the precision oncology diagnostics space. If successful, Known Medicine could shift cancer care from population-based statistics to personalized functional testing. Its platform competes with organoid and ex vivo drug sensitivity assays but offers a scalable, high-throughput solution. The company has yet to disclose funding or partnerships, but its approach has potential to complement liquid biopsies and genomic sequencing. With the growing emphasis on precision medicine, Known Medicine is positioned to capture value if clinical validation studies confirm predictive accuracy. However, challenges remain in standardization, reimbursement, and integration into clinical workflows. The next 12–24 months will be critical for demonstrating real-world utility and securing strategic collaborations.

Upcoming Catalysts (preview)

• Q3 2026Series A Funding Round70% success
• Q4 2026Peer-Reviewed Publication of Validation Data60% success
• Q2 2027Partnership with Major Cancer Center50% success